Skip to main content

Table 4 Microbiologic response at the patient level (ME Population) at test-of-cure visit

From: A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections [Study ID Numbers: 3074A1-301-WW; ClinicalTrials.gov Identifier: NCT00081744]

  Tigecycline Imipenem/cilastatin Difference Tigecycline-Imipenem/cilastatin Test for Noninferiority Test for Differences
Response N % (95% CI) N % (95% CI) % (95% CI) P value  
Eradication 199/247 80.6 (75.1, 85.3) 210/255 82.4 (77.1, 86.8) -1.8 (-9.0, 5.4) 0.0001 0.6892
Persistence 39/247 15.8 (11.5, 20.9) 42/255 16.5 (12.1, 21.6)    
Documented 4/39 10.3 (2.9, 24.2) 1/42 2.4 (0.1, 12.6)    
Presumed 35/39 89.7 (75.8, 97.1) 41/42 97.6 (87.4, 99.9)    
Superinfection 9/247 3.6 (1.7, 6.8) 3/255 1.2 (0.2, 3.4)    
Overall      -1.7 (-8.4, 5.1)*   
  1. *Adjusted difference and its 95%CI are calculated from a generalized linear model with a binomial probability function and an identity link.